Brincidofovir
- Generic Name
- Brincidofovir
- Brand Names
- Tembexa
- Drug Type
- Small Molecule
- Chemical Formula
- C27H52N3O7P
- CAS Number
- 444805-28-1
- Unique Ingredient Identifier
- 6794O900AX
- Background
Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity typically associated with cidofovir therapy. Due to its formulation as a pro-dr...
- Indication
Brincidofovir is indicated for the treatment of human smallpox disease in adult and pediatric patients.
- Associated Conditions
- Variola Major (Smallpox)
- Associated Therapies
- -
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Emergent BioSolutions
- Target Recruit Count
- 44
- Registration Number
- NCT05935917
- Locations
- 🇺🇸
Altasciences, Overland Park, Kansas, United States
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- SymBio Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT05511779
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Chimerix
- Registration Number
- NCT04268966
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Chimerix
- Registration Number
- NCT03532035
- Locations
- 🇺🇸
Brigham and Womens Hospital, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Chigago, Chicago, Illinois, United States
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
- First Posted Date
- 2017-11-13
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 29
- Registration Number
- NCT03339401
- Locations
- 🇺🇸
Joseph M. Sanzari Childrens Hospital-Regional Cancer Care, Hackensack, New Jersey, United States
🇵🇱Uniwerstytecki Azpital Kliniczny we Wroclawiu, Wrocław, Dolnoslaskie, Poland
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
- Conditions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- Chimerix
- Registration Number
- NCT02596997
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Arkansas Medical Center, Little Rock, Arkansas, United States
🇺🇸Methodist University Hospital-BMT program west clinic, Memphis, Tennessee, United States
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 6
- Registration Number
- NCT02439957
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸University of Colorado Hospital/Health Science Center, Aurora, Colorado, United States
🇺🇸St. Vincent Medical Center, Los Angeles, California, United States
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
- Conditions
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 5
- Registration Number
- NCT02439970
- Locations
- 🇺🇸
St. Vincent Medical Center, Los Angeles, California, United States
🇺🇸University of Colorado Hospital/Health Science Center, Aurora, Colorado, United States
🇺🇸Yale New Haven Hospital, New Haven, Connecticut, United States
A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 100
- Registration Number
- NCT02420080
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸Emory University, Atlanta, Georgia, United States
Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 201
- Registration Number
- NCT02087306
- Locations
- 🇺🇸
Children's Hospital, New Orleans, Louisiana, United States
🇺🇸Children's National Health System, Washington, District of Columbia, United States
🇺🇸Montifore Medical Center, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.